id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-333144-gyuh2fvl	Siddiqui, Arif Jamal	Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2	2020-08-05		.txt	text/plain	7806	436	50	Therefore, this review focuses on the current use of various drugs as single agents (hydroxychloroquine, ivermectin, azithromycin, favipiravir, remdesivir, umifenovir, teicoplanin, nitazoxanide, doxycycline, and dexamethasone) or in combinations with immunomodulators additionally. While some drugs have shown therapeutic effect against COVID-19 infection such as hydroxychloroquine (Al-Kofahi et al., 2020; Choudhary & Sharma 2020; Liu et al., 2020; Sinha & Balayla 2020) , azithromycin, (Andreani et al., 2020a; Choudhary & Sharma 2020) ivermectin (Caly et al., 2020; Chaccour et al., 2020; Choudhary & Sharma 2020) and some other antivirals (Asai et al., 2020; Boopathi et al., 2020; Lian et al., 2020) . Consequently, this review will provide an insight and comprehensive view on different therapeutic approaches including combining of different known anti-parasitic drugs, as well as proposing novel suggestions of chemoprophylaxis drug therapy, which can be used in the current treatment and vaccine development strategies against COVID-19 disease.	./cache/cord-333144-gyuh2fvl.txt	./txt/cord-333144-gyuh2fvl.txt